Consistent with these findings, low ABAT transcript levels are associated with resistance to endocrine therapy in ER+ breast cancer [36], as well as a decrease in relapse-free survival [35,37,38] and resistance to chemotherapy [39] in both ER+ and estrogen receptor negative (ER−) tumors. Here, ESR1 is linked to breast cancer.